revealed that (61) FIN56 can stimulate GPX4 degradation, increasing ferroptosis in bladder cancer cells, implying that GPX4 can be exploited as a therapeutic target for bladder cancer medicines. This evidence concerns the gene GPX4 and urinary bladder carcinoma.